dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Rojano Toimil, Alba |
dc.contributor.author | Rivera Esteban, Jesus Manuel |
dc.contributor.author | Manzano Nuñez, Ramiro |
dc.contributor.author | Juan Bañares Sanchez, Juan |
dc.contributor.author | Martinez Selva, David |
dc.contributor.author | Gabriel Medina, Pablo |
dc.contributor.author | Ferrer Costa, Roser |
dc.contributor.author | Pericàs Pulido, Juan Manuel |
dc.contributor.author | Ciudin Mihai, Andreea |
dc.date.accessioned | 2022-09-12T09:30:12Z |
dc.date.available | 2022-09-12T09:30:12Z |
dc.date.issued | 2022-06-08 |
dc.identifier.citation | Rojano-Toimil A, Rivera-Esteban J, Manzano-Nuñez R, Bañares J, Martinez Selva D, Gabriel-Medina P, et al. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. J Clin Med. 2022 Jun 8;11(12):3286. |
dc.identifier.issn | 2077-0383 |
dc.identifier.uri | https://hdl.handle.net/11351/8148 |
dc.description | MODY diabetes; Liver fibrosis; Type 2 diabetes |
dc.description.abstract | Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) have been traditionally linked to one another. Recent studies suggest that NAFLD may be increasingly common in other types of diabetes such as type 1 diabetes (T1DM) and less frequently ketone-prone and Maturity-onset Diabetes of the Young (MODY) diabetes. In this review, we address the relationship between hyperglycemia and insulin resistance and the onset and progression of NAFLD. In addition, despite the high rate of patients with T2DM and other diabetes phenotypes that can alter liver metabolism and consequently develop steatosis, fibrosis, and cirrhosis, NALFD screening is not still implemented in the daily care routine. Incorporating a clinical algorithm created around a simple, non-invasive, cost-effective model would identify high-risk patients. The principle behind managing these patients is to improve insulin resistance and hyperglycemia states with lifestyle changes, weight loss, and new drug therapies. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Journal of Clinical Medicine;11(12) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Fenotip |
dc.subject | Diabetis no-insulinodependent |
dc.subject | Esteatosi hepàtica - Diagnòstic |
dc.subject.mesh | Diabetes Mellitus, Type 2 |
dc.subject.mesh | Non-alcoholic Fatty Liver Disease |
dc.subject.mesh | /diagnosis |
dc.subject.mesh | Phenotype |
dc.title | When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/jcm11123286 |
dc.subject.decs | diabetes mellitus tipo II |
dc.subject.decs | esteatosis hepática no alcohólica |
dc.subject.decs | /diagnóstico |
dc.subject.decs | fenotipo |
dc.relation.publishversion | https://doi.org/10.3390/jcm11123286 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Rojano-Toimil A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rivera-Esteban J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Manzano-Nuñez R, Bañares J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Martinez Selva D] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Spanish Network of Biomedical Research Centers, Diabetes and Metabolic Associated Disorders (CIBERdem), Madrid, Spain. [Gabriel-Medina P] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferrer R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pericàs JM] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Network of Biomedical Research Centers, Liver and Digestive Diseases (CIBERehd), Madrid, Spain. [Ciudin A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Network of Biomedical Research Centers, Diabetes and Metabolic Associated Disorders (CIBERdem), Madrid, Spain |
dc.identifier.pmid | 35743358 |
dc.identifier.wos | 000817683200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |